FluoGuide gets green light to proceed to fourth dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma
Copenhagen, Denmark, 17 February 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee have approved initiation of the fourth dose level in the ongoing clinical phase I/II trial evaluating safety and efficacy of FG001 in patients with high grade glioma undergoing neurosurgery.Evaluation of the results from the third dose level of FG001, including data from three patients, have been finalized and reported to the dose escalation committee. The dose escalation committee has today given their approval to proceed and enroll patients at the